Indivior Indivior’s miracle drug wears off Features Indivior’s opioid addiction treatment has been exposed to generic competition. Can the drugmaker fight back? Alice Gråhns reports. Features If you’d invested in: Indivior and Next Features Drugmaker Indivior is on the up, while retailer Next, once a favourite with investors, has lost its way. By Ben Judge Published 24 February 17 Features
